Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$424M |
| 2 |
Bath & Body Works
BBWI
|
+$342M |
| 3 |
Home Depot
HD
|
+$259M |
| 4 |
GE Aerospace
GE
|
+$247M |
| 5 |
Palo Alto Networks
PANW
|
+$214M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
+$917M |
| 2 |
ARMH
ARM HOLDINGS PLC ADS
ARMH
|
+$396M |
| 3 |
Citigroup
C
|
+$377M |
| 4 |
Sherwin-Williams
SHW
|
+$292M |
| 5 |
Starbucks
SBUX
|
+$260M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 20.46% |
| 2 | Healthcare | 16.66% |
| 3 | Communication Services | 14.21% |
| 4 | Technology | 13.93% |
| 5 | Financials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
BioCryst Pharmaceuticals
BCRX
$2.48B
| $3.84M | ﹤0.01% |
1,357,604
+9,041
| +0.7% | +$40.1K |
|
|
GBT
502
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.76M | ﹤0.01% |
237,317
-75,505
| -24% | -$1.34M |
|
503
MacroGenics
MGNX
$245M
| $3.68M | ﹤0.01% |
196,435
-70,973
| -27% | -$1.35M |
|
504
Qualys
QLYS
$4.78B
| $3.52M | ﹤0.01% |
138,894
-114,836
| -45% | -$2.98M |
|
505
Intel
INTC
$435B
| $3.34M | ﹤0.01% |
103,378
+2,794
| +3% | +$85.7K |
|
|
BCR
506
DELISTED
CR Bard Inc.
BCR
| $3.33M | ﹤0.01% |
+16,422
| New | +$3.1M |
|
507
Elevance Health
ELV
$83.7B
| $3.28M | ﹤0.01% |
23,598
-2,297
| -9% | -$307K |
|
|
ADAP
508
DELISTED
Adaptimmune Therapeutics
ADAP
| $3.28M | ﹤0.01% |
402,967
-83,981
| -17% | -$687K |
|
509
Berkshire Hathaway Class B
BRK.B
$1.11T
| $3.24M | ﹤0.01% |
22,814
-2,748
| -11% | -$364K |
|
510
Johnson & Johnson
JNJ
$643B
| $3.19M | ﹤0.01% |
29,483
-4,587
| -13% | -$475K |
|
511
Regenxbio
RGNX
$615M
| $3.16M | ﹤0.01% |
292,388
-45,690
| -14% | -$585K |
|
512
Markel Group
MKL
$25.5B
| $3.16M | ﹤0.01% |
3,540
+1,138
| +47% | +$978K |
|
513
HF Sinclair
DINO
$16.1B
| $3.15M | ﹤0.01% |
89,183
+35,739
| +67% | +$1.23M |
|
|
BNY
514
Bank of New York Mellon
BNY
$106B
| $3.13M | ﹤0.01% |
85,070
+5,649
| +7% | +$205K |
|
515
Gartner
IT
$10.4B
| $3.13M | ﹤0.01% |
34,999
+259
| +0.7% | +$21.9K |
|
516
Cardinal Health
CAH
$54.5B
| $3.1M | ﹤0.01% |
+37,812
| New | +$3.07M |
|
517
General Mills
GIS
$20.1B
| $3.09M | ﹤0.01% |
+48,830
| New | +$2.84M |
|
518
Stryker
SYK
$133B
| $2.91M | ﹤0.01% |
+27,130
| New | +$2.67M |
|
519
Plains GP Holdings
PAGP
$5.2B
| $2.83M | ﹤0.01% |
122,364
-629,045
| -84% | -$12.9M |
|
|
RRMS
520
DELISTED
ROSE ROCK MIDSTREAM L P COM UNIT REPSTG LTD (DE)
RRMS
| $2.69M | ﹤0.01% |
226,690
+107,224
| +90% | +$1.24M |
|
|
INNL
521
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $2.35M | ﹤0.01% |
279,326
+1,887
| +0.7% | +$15.7K |
|
522
State Street SPDR S&P Metals & Mining ETF
XME
$3.9B
| $2.28M | ﹤0.01% |
111,285
+15,067
| +16% | +$244K |
|
523
Targa Resources
TRGP
$56.2B
| $2.27M | ﹤0.01% |
+76,033
| New | +$1.81M |
|
|
MRSH
524
Marsh
MRSH
$91.7B
| $2.23M | ﹤0.01% |
+36,694
| New | +$2.05M |
|
525
Webster Financial
WBS
$12.5B
| $2.2M | ﹤0.01% |
61,238
+258
| +0.4% | +$8.84K |
|
Similar funds
Jennison Associates's Q1 2016 Portfolio in Review
As of Q1 2016, Jennison Associates held 710 positions worth $95.3B, down 6.5% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q1 2016 filing shows 56 new, 303 increased, 241 reduced and 102 closed positions. Its largest new stake was Procter & Gamble: 1,657,581 shares worth $136M. The largest sale was LinkedIn Corporation, an estimated $917M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Communication Services.
- Jennison Associates's largest Q1 2016 buy was Procter & Gamble: 1,657,581 shares worth $136M.
- Jennison Associates added most to Microsoft in Q1 2016, an estimated $424M increase.
- Jennison Associates's biggest Q1 2016 reduction was LinkedIn Corporation, cutting an estimated $917M.
- Jennison Associates fully exited Sherwin-Williams in Q1 2016, selling an estimated $292M.
- Jennison Associates's ten largest holdings make up 24% of its $95.3B portfolio in Q1 2016.
- Jennison Associates opened 56 new positions and closed 102 in Q1 2016.
- Jennison Associates's portfolio value fell 6.5% quarter-over-quarter to $95.3B.
Based on Jennison Associates's 13F filing for Q1 2016, filed 3 May 2016.